Cairo Pharmaceuticals results, Fiscal year 2022
Net profit, assets, equity and cash flow for Fiscal year 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit166 millionEGP · +33.3% vs the same period a year earlier
Total assets1.17 billionEGP · +9.4% vs the same period a year earlier
Shareholders' equity794 millionEGP · +12.8% vs the same period a year earlier
Operating cash flow51.83 millionEGP · −68.1% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Fiscal year 2022 was about 166 million EGP, up +33.3% from 124 million EGP in Fiscal year 2021.
- Total assets at the end of Fiscal year 2022 were about 1.17 billion EGP, and shareholders' equity about 794 million EGP.
- Operating cash flow for Fiscal year 2022 was positive at 51.83 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2021Change
Net profit166 million124 million+33.3%
Gross profit337 million268 million+25.9%
Total assets1.17 billion1.07 billion+9.4%
Total liabilities375 million365 million+2.8%
Shareholders' equity794 million704 million+12.8%
Total liabilities and equity1.17 billion1.07 billion+9.4%
Operating cash flow51.83 million162 million−68.1%
Investing cash flow3.49 million-35.13 million+109.9%
Financing cash flow-75.2 million-77.73 million+3.2%
Net change in cash-19.89 million49.39 million−140.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy